Nanoscope Therapeutics Data to be Presented at 2025 American Society of Retina Specialists Annual Scientific Meeting
126-week results from RESTORE follow-up study (REMAIN) to highlight the extended efficacy and safety of Nanoscope's MCO-010 optogenetic therapy for Retinitis Pigmentosa
DALLAS, July 28, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering severe vision loss from retinal degenerative diseases, announced that its multi-characteristic opsin (MCO) gene therapy platform will be featured in a presentation by Dr. David S. Liao at the 2025 American Society of Retina Specialists Annual Scientific Meeting, taking place July 30-August 2, 2025 at the Long Beach Convention Center in Long Beach, California.
Dr. Liao will present 126-week data on the strong efficacy and safety profile of MCO-010 in treating retinitis pigmentosa (RP) patients via a one time, in-office intravitreal injection without the need for genetic testing. Nanoscope recently initiated a rolling submission of a Biologics License Application (BLA) to the FDA for MCO-010 for the treatment of severe vision loss due to RP. The data, from Nanoscope's RESTORE follow-up study (REMAIN), form the backbone of Nanoscope's BLA rolling submission.
Details for the presentation are as follows:
Title: | Extended Efficacy and Safety of MCO-010 Optogenetic Therapy for RP: 126-Week Results From the RESTORE Follow-Up Study (REMAIN) |
Session Title: | Hereditary Retinal Disease & Genetics Symposium 1 |
Session Date: | Friday, August 1 |
Session Time: | 4:50 to 4:53 pm PDT |
Presenter: |
"We are excited to have this 126-week data presented at ASRS, especially with our recent BLA announcement," said Dr. Samuel Barone, Chief Medical Officer for Nanoscope. "This will be a great opportunity for the ASRS community to discuss our data and its potential impact on RP patients."
For more information on MCO-010 and Nanoscope Therapeutics visit: www.nanostherapeutics.com.
About Nanoscope Therapeutics
Nanoscope Therapeutics is developing gene-agnostic, vision-restoring optogenetic therapy for millions of patients blinded by retinal degenerative diseases. Following positive results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for retinitis pigmentosa (RP) (NCT04945772), a rolling BLA submission to the FDA has been initiated. If approved, MCO-010 has the potential to be the standard of care for RP patients, administered as a one-time, in-office injection without the need for genetic testing. The company has also shown promising results in the STARLIGHT Phase 2 clinical trial of MCO-010 in Stargardt disease (SD) (NCT05417126) and plans to initiate a Phase 3 registrational trial in 2025. MCO-010 has received FDA Fast Track and Orphan Drug designations for both RP and SD. Preclinical programs include Leber congenital amaurosis (LCA), in IND-enabling studies, as well as an IND-ready asset for geographic atrophy (GA).
Contact:
Nanoscope Therapeutics
(817) 857-1186
PR@nanostherapeutics.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-therapeutics-data-to-be-presented-at-2025-american-society-of-retina-specialists-annual-scientific-meeting-302514594.html
SOURCE Nanoscope Therapeutics